Harel Insurance Investments & Financial Services Ltd. lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 20.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,200 shares of the biopharmaceutical company’s stock after selling 814 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.’s holdings in Gilead Sciences were worth $208,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. BlackRock Inc. increased its holdings in shares of Gilead Sciences by 2.2% in the fourth quarter. BlackRock Inc. now owns 104,186,077 shares of the biopharmaceutical company’s stock valued at $6,516,839,000 after purchasing an additional 2,195,948 shares during the period. Vanguard Group Inc increased its holdings in shares of Gilead Sciences by 1.1% in the third quarter. Vanguard Group Inc now owns 97,167,329 shares of the biopharmaceutical company’s stock valued at $7,502,290,000 after purchasing an additional 1,071,619 shares during the period. Oregon Public Employees Retirement Fund increased its holdings in shares of Gilead Sciences by 5,733.7% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 28,988,297 shares of the biopharmaceutical company’s stock valued at $463,000 after purchasing an additional 28,491,386 shares during the period. Northern Trust Corp grew its holdings in Gilead Sciences by 2.3% during the fourth quarter. Northern Trust Corp now owns 16,987,641 shares of the biopharmaceutical company’s stock worth $1,062,577,000 after acquiring an additional 380,928 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Gilead Sciences by 5.2% during the fourth quarter. Geode Capital Management LLC now owns 16,867,065 shares of the biopharmaceutical company’s stock worth $1,053,332,000 after acquiring an additional 835,915 shares during the period. Institutional investors own 80.20% of the company’s stock.
A number of research analysts recently weighed in on GILD shares. ValuEngine lowered Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, February 13th. Mizuho set a $88.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a report on Friday, March 22nd. BidaskClub lowered Gilead Sciences from a “buy” rating to a “hold” rating in a report on Thursday, February 7th. Wells Fargo & Co dropped their price objective on Gilead Sciences from $95.00 to $89.00 and set an “outperform” rating on the stock in a report on Tuesday, February 5th. Finally, Oppenheimer raised Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 price objective on the stock in a report on Thursday, January 3rd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $82.12.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.70 by ($0.26). Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.52 billion. During the same quarter last year, the company posted $1.78 earnings per share. The business’s quarterly revenue was down 2.6% compared to the same quarter last year. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 6.23 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.57. This represents a $2.52 annualized dividend and a yield of 4.00%. Gilead Sciences’s dividend payout ratio is 40.98%.
In other Gilead Sciences news, Director John Francis Cogan sold 2,700 shares of the company’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $64.14, for a total transaction of $173,178.00. Following the completion of the sale, the director now directly owns 57,560 shares in the company, valued at $3,691,898.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gayle E. Wilson sold 19,068 shares of the company’s stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $67.08, for a total value of $1,279,081.44. Following the sale, the director now owns 143,567 shares of the company’s stock, valued at $9,630,474.36. The disclosure for this sale can be found here. Insiders have sold 42,102 shares of company stock valued at $2,787,375 over the last 90 days. 0.20% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: This report was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/04/22/harel-insurance-investments-financial-services-ltd-trims-holdings-in-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.